TP53 and cancer: This includes intra-peritoneal injection (IP) of a Tat-conjugated all-D retro-inverso (ri)-p53 [30] and an all-D undecaarginine (R11)-conjugated p53-ri-hemagglutinin-2 (HA-2) [31] to a peritoneal carcinomatosis mouse model, both of which positively affect apoptosis in the cancer cells, thereby prolonging survival of the treated mice.